Aarti Pharmalabs Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Aarti Pharmalabs Ltd is ₹ 744.25 as of 30 Apr 15:30 . The P/E Ratio of Aarti Pharmalabs Ltd changed from 12.9 on March 2023 to 24.9 on March 2025 . This represents a CAGR of 24.51% over 3 yearsThe P/E Ratio of Remus Pharmaceuticals Ltd changed from 49.4 on March 2024 to 45.4 on March 2025 . This represents a CAGR of -4.13% over 2 years The Market Cap of Aarti Pharmalabs Ltd changed from ₹ 2489 crore on March 2023 to ₹ 6784 crore on March 2025 . This represents a CAGR of 39.69% over 3 yearsThe Market Cap of Remus Pharmaceuticals Ltd changed from ₹ 1016 crore on March 2024 to ₹ 1319 crore on March 2025 . This represents a CAGR of 13.93% over 2 years The revenue of Aarti Pharmalabs Ltd for the Dec '25 is ₹ 436.83 crore as compare to the Sep '25 revenue of ₹ 418.39 crore. This represent the growth of 4.41% The revenue of Remus Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Aarti Pharmalabs Ltd for the Dec '25 is ₹ 104.07 crore as compare to the Sep '25 ebitda of ₹ 74.13 crore. This represent the growth of 40.39% The ebitda of Remus Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Aarti Pharmalabs Ltd changed from ₹ 55.45 crore to ₹ 47.96 crore over 7 quarters. This represents a CAGR of -7.96% The net profit of Remus Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Aarti Pharmalabs Ltd changed from 10.55 % on March 2023 to 17.61 % on March 2025 . This represents a CAGR of 18.62% over 3 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 years .

About Aarti Pharmalabs Ltd

Aarti Pharmalabs Limited was initially incorporated as 'Aarti Organics Limited' in 2019.
The name of the Company was changed to Aarti Pharmachem Limited from Aarti Organics Limited' in July, 2021 and to Aarti Pharmalabs Limited in 2022.
Company is a manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives situated in India.
It specialise in developing and manufacturing Highly Potent Active Pharmaceutical Ingredients (HPAPIs) critical for various therapeutic segments such as Anti-cancer, Anti-Asthma, Anti-Hypertensive etc. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016.

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

FAQs for the comparison of Aarti Pharmalabs Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Aarti Pharmalabs Ltd or Remus Pharmaceuticals Ltd?

Market cap of Aarti Pharmalabs Ltd is 6,747 Cr while Market cap of Remus Pharmaceuticals Ltd is 807 Cr

What are the key factors driving the stock performance of Aarti Pharmalabs Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Aarti Pharmalabs Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Pharmalabs Ltd and Remus Pharmaceuticals Ltd?

As of May 3, 2026, the Aarti Pharmalabs Ltd stock price is INR ₹744.25. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹685.3.

How do dividend payouts of Aarti Pharmalabs Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Aarti Pharmalabs Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.